Entrusted financial announcement
Release time:
2021-05-20
证券简称:尖峰集团 证券代码:600668 编号:临2021-002
浙江尖峰集团股份有限公司
委托理财公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
- 委托理财受托方:中国农业银行金华江北支行
- 委托理财金额:8,000万元人民币
- 委托理财产品名称:汇利丰2021年第4166期对公定制人民币结构性存 款产品
- 委托理财投资类型:保本浮动收益型结构性存款
- 委托理财期限:2021年02月02日—2021年04月30日
- 履行的审议程序:2019年4月26日,公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长利用自有资金进行委托理财的议案》。授权公司董事长行使不超过人民币5亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过5亿元,每笔委托理财的期限均不得超过12个月。详见本公司在2019年4月30日在上海证券交易所网站等披露的《关于授权公司董事长利用自有资金进行委托理财的公告》(临2019-012)。
一、本次委托理财概况
(一)委托理财目的
公司在不影响主营业务的正常开展、日常运营资金周转需要和资金安全的前提下,使用暂时闲置自有资金8,000万元购买中国农业银行金华江北支行发售的汇利丰2021年第4166期对公定制人民币结构性存款产品。本产品为保本浮动收益型存款产品,安全性高、流动性好、风险性低。公司通过进行适度的低风险理财产品投资业务,有利于提高资金使用效率,且获得一定的理财收益。
(二)资金来源
本次委托理财的资金来源系公司自有资金。
(三)委托理财产品的基本情况
|
受托方 名称 |
产品 类型 |
产品 名称 |
金额 (万元) |
预计年化 收益率 |
预计收益金额 (万元) |
|
中国农业银行金华江北支行 |
人民币结构性存款产品 |
汇利丰2021年第4166期对公定制人民币结构性存款产品 |
8,000 |
1.50%—3.30% |
28.60-62.93 |
|
产品 期限 |
收益 类型 |
结构化 安排 |
参考年化 收益率 |
预计收益 (万元) |
是否构成 关联交易 |
|
87天 |
保本浮动收益型 |
无 |
1.50%—3.30% |
28.60-62.93 |
否 |
(四)公司对委托理财相关风险的内部控制
1、委托理财情况由公司审计部门进行日常监督,定期对公司委托理财的进展情况、盈亏情况、风险控制情况和资金使用情况进行审计、核实。
2、公司进行委托理财,应当选择资信、财务状况良好、盈利能力强的合格专业理财机构作为受托方,并与受托方签订书面合同,明确委托理财的金额、期间、投资品种、双方的权利义务及法律责任等,必要时要求提供担保。公司董事会指派公司财务负责人跟踪委托理财的进展情况及投资安全状况。财务负责人发现公司委托理财出现异常情况时应当及时向董事会报告,以便董事会立即采取有效措施回收资金,避免或减少公司损失。
3、公司独立董事可以对委托理财情况进行检查。独立董事在公司内部审计核查的基础上,以董事会审计委员会核查为主,必要时由二名以上独立董事提议,有权聘任独立的外部审计机构进行委托理财的专项审计。独立董事应对提交董事会审议的委托理财事项发表独立意见。
4、公司监事会有权对公司委托理财情况进行定期或不定期的检查。如发现违规操作情况可提议召开董事会审议停止公司的相关投资活动。
5、公司委托理财具体执行人员及其他知情人员在相关信息公开披露前不得将公司投资情况透露给其他个人或组织,但法律、法规或规范性文件另有规定的除外。
6、凡违反相关法律法规、本制度及公司其他规定或由于工作不尽职,致使公司遭受损失或收益低于预期,将视具体情况,追究相关人员的责任。
本次公司购买中国农业银行发行的保本浮动收益型结构性存款,在前述董事会对董事长的授权范围内,该产品风险程度低,符合公司内部资金管理要求。
二、本次委托理财的具体情况
(一)委托理财合同主要条款
客户:浙江尖峰集团股份有限公司
银行:中国农业银行金华江北支行
|
产品名称 |
汇利丰2021年第4166期对公定制人民币结构性存款产品 |
|
产品代码 |
2021年第4166期 |
|
挂钩标的 |
欧元/美元汇率 |
|
产品期限 |
87天 |
|
产品类型 |
保本浮动收益 |
|
本金保证 |
本结构性存款产品由中国农业银行为投资人提供到期本金担保,100%保障投资者本金安全。 |
|
存款起息日 |
2021年02月02日 |
|
存款到期日 |
2021年04月30日 |
|
运作模式 |
本结构性存款按照存款管理,纳入存款准备金和存款保险保费的缴纳范围,收益部分与外汇期权挂钩获得浮动收益。 |
|
产品收益说明 |
(1)如在观察期内,欧元/美元汇率始终位于参考区间内(不包括区间临界值),则到期时预期可实现的投资年化收益率为3.30%/年。扣除中国农业银行收取的管理费0.00%/年后,实际支付给投资者的净收益率为3.30%/年。 (2)如在观察期内,欧元/美元汇率突破了参考区间(包括达到区间临界值情况),则到期时预期可实现的投资年化收益率为1.50%/年。扣除中国农业银行收取的管理费0.00%/年后,实际支付给投资者的净收益率为1.50%/年。 投资人收益=结构性存款产品本金×实际支付给投资者的净年化收益率×结构性存款实际天数÷365,精确到小数点后2 位,具体以中国农业银行股份有限公司实际派发为准。 |
|
欧元/美元汇率 |
取自每周一悉尼时间上午5 点至每周五纽约时间下午5 点之间,银行间外汇市场欧元/美元汇率的报价。 |
|
观察期 |
产品起息日北京时间上午10 点至产品到期前两个工作日北京时间下午2 点之间。 |
|
参考区间 |
欧元/美元汇率( S-0.0749,S+0.0749 )。其中S 为产品起息日北京时间上午10:00 彭博BFIX页面欧元中间价(四舍五入取到小数点后四位)。 |
|
还本付息 |
本结构性存款产品到期日后2 个银行工作日内一次性支付结构性存款产品本金及收益。遇非银行工作日时顺延。 本结构性存款产品到期前不分配收益。 |
|
到期清算 |
结构性存款产品约定持有期到期日/产品终止日/提前终止日至结构性存款资金返还到账日 (不含)为结构性存款产品清算期,清算期内结构性存款资金不计付利息。 |
|
投资人结构性存款收益情景分析 |
投资人认购金额10000000 元人民币 (1)情景1:最好情景 如在观察期内,欧元/美元汇率始终位于参考区间内(不包括区间临界值), 投资人获得净年化收益率=3.30% 投资者到期获得结构性存款本金+利息=10000000+10000000*3.30%*87/365=10,078,657.53元人民币 (2)情景2:最差情景 如在观察期内,欧元/美元汇率曾突破了参考区间(包括达到区间临界值情况),投资人获得净年化收益率=1.50% 投资者到期获得结构性存款本金+利息=10000000+10000000* 1.50%*87/365=10,035,753.42元人民币 本产品为保本浮动收益结构性存款产品,到期保证100%本金安全,收益部分挂钩汇率从而 具有市场风险,因而可能无法获得最高预期收益率。您应当充分认识投资风险,谨慎投资。 |
|
提前终止条款 |
本结构性存款产品投资者无权提前终止。在产品存续期内,如市场情况、法律法规、监管规定出现重大变更,中国农业银行有权利但无义务提前终止本结构性存款产品。如果中国农业银行提前终止本结构性存款产品,中国农业银行将在提前终止日前2 个工作日内向投资者发出提前终止公告。 |
|
提前终止清算 |
如农业银行决定提前终止此产品,提前终止日即为产品实际到期日,本结构性存款产品依产品实际投资收益率和实际结构性存款天数进行清算,具体以农业银行相关通告为准。 中国农业银行将在提前终止日后2 个工作日内将结构性存款产品本金及收益(如有)划转至投资者原账户。 |
|
申购和赎回本 |
本结构性存款产品在产品到期日之前不对投资者开放产品申购和赎回。 |
(二)委托理财的资金投向
本次公司委托理财的资金投向为中国农业银行结构性存款产品。
(三)风险控制分析
公司本次使用自有资金购买中国农业银行金华江北支行发售的保本浮动收益型结构性存款,在公司第十届董事会第10次会议授权董事长决策范围之内。公司财务部建立台账负责对短期理财产品进行管理,建立健全会计账目,做好资金使用的财务核算工作。公司在本次交易后将履行信息披露义务,并实时跟踪进展情况及时披露。
中国农业银行结构性存款属于保本浮动收益型产品,中国农业银行江北支行承诺保障结构性存款本金,因此该产品风险程度较低,符合公司《委托理财管理制度》的要求。
三、委托理财受托方的情况
公司本次委托理财受托方为中国农业银行股份有限公司。中国农业银行股份有限公司为上海证券交易所上市金融机构(股票代码为:601288),与本公司、控股股东及实际控制人之间在产权、业务、资产、债权债务、人员等方面均不存在关联关系。
四、对公司的影响
(一)本公司最近一年又一期主要财务指标
单位:万元
|
项目 |
2019年12月31日 |
2020年9月30日 |
|
总资产 |
547,517.79 |
610,942.80 |
|
总负债 |
139,487.88 |
157,117.13 |
|
归属于公司股东的净资产 |
378,910.99 |
426,929.92 |
|
|
2019年度 |
2020年1-9月 |
|
经营性现金流量净额 |
51,998.13 |
24,611.67 |
|
营业收入 |
354,753.76 |
224,065.44 |
|
归属于公司股东的净利润 |
72,468.81 |
51,623.07 |
公司本次购买中国农业银行结构性存款理财产品是在不影响主营业务的正常开展、日常运营资金周转需要和资金安全的前提下,使用短期闲置自有资金进行委托理财业务,有利于提高公司资金使用效率。
(二)截止2020年9月30日,公司货币资金为26,471.11万元,本次购买中国农业银行结构性存款支付的金额占最近一期期末货币资金的30.22%,对本公司未来主营业务、财务状况、经营成果和现金流量等不会造成重大的影响。
(三)根据企业会计准则第22号—《金融工具确认和计量》规定,该结构性银行存款符合以摊余成本计量的金融资产,列示于资产负债表—其他流动资产,利息收益计入利润表—投资收益。
五、风险提示
尽管本公司购买的结构性存款属于短期保本浮动收益型的低风险理财产品,但金融市场受宏观经济影响较大,不排除该项投资受到市场风险、信用风险、政策风险、流动性风险、不可抗力风险等风险从而影响收益。
六、独立董事意见
公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长决定委托理财的议案》,独立董事发表了独立意见,认为:该决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
七、截至本公告日,公司最近十二个月使用自有资金或募集资金委托理财的情况 单位:万元
|
序号 |
理财产品类型 |
实际投入 金额 |
实际收回 本金 |
实际收益 |
尚未收回 本金金额 |
|
1 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
5,000.00 |
50.55 |
/ |
|
2 |
结构性存款 |
5,000.00 |
5,000.00 |
18.74 |
/ |
|
3 |
慧盈人民币单位结构性存款产品 |
5,000.00 |
5,000.00 |
49.91 |
/ |
|
4 |
薪加薪16号人民币结构性存款产品 |
10,000.00 |
10,000.00 |
100.97 |
/ |
|
5 |
慧盈人民币单位结构性存款产品 |
10,000.00 |
10,000.00 |
100.82 |
/ |
|
6 |
慧盈人民币单位结构性存款产品 |
10,000.00 |
10,000.00 |
92.66 |
/ |
|
7 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
5,000.00 |
42.67 |
/ |
|
8 |
慧盈人民币单位结构性存款产品 |
10,000.00 |
10,000.00 |
79.59 |
/ |
|
9 |
薪加薪16号人民币结构性存款产品 |
15,000.00 |
15,000.00 |
131.34 |
/ |
|
10 |
慧盈人民币单位结构性存款产品 |
10,000.00 |
10,000.00 |
39.07 |
/ |
|
11 |
汇利丰2020年6156期对公定制人民币结构性存款产品 |
7,000.00 |
7,000.00 |
52.16 |
/ |
|
12 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
5,000.00 |
48.97 |
/ |
|
13 |
招商银行结构性存款NHZ00043 |
5,000.00 |
/ |
/ |
5,000.00 |
|
14 |
薪加薪16号人民币结构性存款产品 |
10,000.00 |
/ |
/ |
10,000.00 |
|
15 |
招商银行结构性存款NHZ00047 |
5,000.00 |
/ |
/ |
5,000.00 |
|
16 |
渤海银行WBS200068号结构性存款 |
10,000.00 |
10,000.00 |
29.73 |
/ |
|
17 |
薪加薪16号人民币结构性存款产品 |
5,000.00 |
/ |
/ |
5,000.00 |
|
18 |
招商银行结构性存款NHZ00113 |
10,000.00 |
10,000.00 |
24.04 |
/ |
|
19 |
汇利丰2021年第4166期对公定制人民币结构性存款 |
8,000.00 |
/ |
/ |
8,000.00 |
|
合计 |
150,000.00 |
117,000.00 |
861.22 |
33,000.00 |
|
|
最近12个月内单日最高投入金额 |
50,000.00 |
||||
|
最近12个月内单日最高投入金额/最近一年净资产(%) |
13.20 |
||||
|
最近12个月委托理财累计收益/最近一年净利润(%) |
1.19 |
||||
|
目前已使用的理财额度 |
33,000.00 |
||||
|
尚未使用的理财额度 |
17,000.00 |
||||
|
总理财额度 |
50,000.00 |
||||
特此公告
浙江尖峰集团股份有限公司
董事会
二〇二一年一月三十日
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05